Methods Multicenter, retrospective cohort study including patients> 18 years hospitalized
between 7/1/2021-8/1/2022 with confirmed COVID-19, with 5, 6 and 7 points of WHO Ordinal …

GALVALISI, Nazareno et al. From publications to every day clinical practice: tocilizumab in
patients with severe COVID-19. Medicina (B. Aires)[online]. 2022, vol. 82, n. 5, pp. 659-666 …

Introduction: there is evidence on the effectiveness and safety of tocilizumab (TZC) used in
combination with systemic corticosteroids for severe SARS-CoV-2 pneumonia treatment …

Background Controversy remains about the efficacy of tocilizumab (TCZ) for the treatment of
severe COVID-19. We aimed to analyze the profile of TCZ-respondent patients. Methods We …

Recently it has been demonstrated the clinical effectiveness of tocilizumab (TCZ) associated
with systemic steroids for the treatment of severe SARS-CoV-2 pneumonia with rapid …

Background: We report the long-term outcomes, changes in laboratory parameters, the
incidence of secondary nosocomial infections and treatment cost of a Spanish cohort of …

Recently it has been demonstrated the clinical effectiveness of tocilizumab (TCZ) associated
with systemic steroids for the treatment of severe SARS-CoV-2 pneumonia with rapid …

Resumen MARTINEZ-GUERRA, Bernardo A. et al. Effect of Tocilizumab in Mortality among
Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center …

Background SARS-CoV-2 is associated with a severe inflammatory response contributing to
respiratory and systemic manifestations, morbidity, and mortality in patients with coronavirus …

Introducción: El objetivo del estudio fue estudiar la utilización de tocilizumab en un centro
hospitalario Método: Estudio de cohortes retrospectivo que incluyó pacientes ingresados …